Polyinosinic-polycytidylic acid potassium  (Synonyms: Poly(I:C) potassium)

Polyinosinic-polycytidylic acid potassium (Poly(I:C) potassium) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid potassium can directly trigger cancer cells to undergoApoptosis^[1][2][3].

Polyinosinic-polycytidylic acid potassium (20 ng/mL; 24 hours; WM793, WM278, WM239A, WM9 and 1205Lu cells) inhibits cell growth^[1].
Polyinosinic-polycytidylic acid potassium (200 ng/mL; 24 hours; 1205Lu cells) induces apoptosis in 1205Lu cells^[1].
Polyinosinic-polycytidylic acid potassium (3 ng/mL; 24 hours; 1205Lu cells) induces IFN-β expression in melanoma cells. Silencing of RIG-I and MDA-5 confirmed that induction of IFN-β by Polyinosinic-polycytidylic acid required RIG-I and MDA-5, respectively, and that required IPS-1^[1].
Polyinosinic-polycytidylic acid potassium is prepared for injection by resuspending in sterile saline, heating to 50 °C at a concentration of 2 mg/ml to ensure complete solubilisation and then allowing to cool naturally to room temperature to ensure proper annealing of double-stranded RNA. Poly I:C is stored at -20 °C until use^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Polyinosinic-polycytidylic acid potassium (50 µg; i.v.; on days 3, 6, and 9 after tumor inoculation) shows antitumor activity in NOD/SCID immunodeficient mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

(C₁₀H₁₃N₄O₈P)x.(C₉H₁₄N₃O₈P)x.xK

31852-29-6

O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N2C3=C(C(N=CN3)=O)N=C2.O[C@@H]4[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]4N5C(N=C(C=C5)N)=O.[x].[x]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Besch R, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest. 2009 Aug;119(8):2399-411.  [Content Brief]

  [2]. Cheng YS, et al. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther. 2010 Dec 15;10(12):1219-23.  [Content Brief]

  [3]. Robert Field, et al. Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun. 2010 Aug;24(6):996-1007.  [Content Brief]